Three leading health and pharmaceutical companies — GlaxoSmithKline, Teva, Takeda – and EcoVadis, the leading provider of sustainability risk and performance ratings for global supply chains, recently announced the launch of the Responsible Health Initiative. Its purpose is to use collaboration and technology to improve visibility, efficiency and sustainability impact of the global health supply chain.
“As business models across the health and pharmaceutical industries continue to evolve and overlap, it makes sense for organizations to focus on shared needs, goals and opportunities in sustainability, and act on them through the collective industry supply chain,” said Pierre-Francois Thaler, Co-CEO and Co-Founder of EcoVadis. “Peer collaboration is a proven model for enabling companies in any sector to easily harmonize sustainability performance measurement and extend visibility. We are confident the Responsible Health Initiative will help create the networked impact the healthcare industry needs.”
An official note said this effort will increase shared value across the industry’s supply chain by enabling key players in the global health sector to boost not only their own sustainability
The shared vision for the Responsible Health Initiative includes:
- Harmonizing industry standards for online CSR assessments, with reliable indicators and global benchmarks
- Adopting a common platform to ease sharing of CSR performance among suppliers/ third parties and RHI members
- Implementing shared tools to boost supplier engagement and improvement plans
- Working together to reduce risk and increase visibility in the supply chain
Organizations in the Responsible Health Initiative will be equipped to access untapped sustainability potential across the industry supply chain, identify high-performing suppliers and best practices, reduce operational disruptions, mitigate risk, and drive value with suppliers.
